# US 10,117,908 B2 · Suppression of cellular transformation and dysplasia by topical application of lefty

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,908 B2
- Document ID: US10117908B2
- Status: Granted
- Kind: B2
- Application number: 15/029,829
- Filed: 2014-10-17
- Published: 2016-09-29
- Granted: 2018-11-06
- Earliest claimed: 2013-10-17
- Assignees: Grant Labs, Inc.
- Applicants: Grant Labs, Inc.
- Inventors: Charles E. Craft
- Web page: https://patentgrep.com/patent/US10117908B2

## CPC

- A61K 38/18: Growth factors; Growth regulators
- A61K 8/042: {Gels}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 38/1709: {from mammals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- C07K 14/475: Growth factors; Growth regulators
- C07K 14/495: Transforming growth factor [TGF]
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to suppression of cellular transformation and dysplasia by topical application of Lefty. In particular, the present disclosure provides compositions and methods for topically applying Lefty to treat and prevent cancers.

## Claims

### Claim 1

A method of treating melanoma in a subject comprising topically contacting said subject with a composition comprising Lefty, ethanol, trolamine, carbomer, methyl paraben, propyl paraben, and phosphate buffered saline (PBS).

### Claim 2 (depends on 1)

The method of claim 1, wherein said contacting comprises contacting a nevi.

### Claim 3 (depends on 1)

The method of claim 1, wherein said contacting comprises contacting a pre-cancerous lesion.

### Claim 4 (depends on 1)

The method of claim 1, wherein said contacting comprises contacting a site of removal of a cancerous or precancerous lesion.

### Claim 5 (depends on 1)

The method of claim 1, wherein said contacting is performed continuously over a period of weeks or months.

### Claim 6 (depends on 1)

The method of claim 1, wherein said Lefty is glycosylated.

### Claim 7 (depends on 1)

The method of claim 1, wherein said composition comprises histamine.

### Claim 8 (depends on 1)

The method of claim 1, wherein said Lefty is present in said composition at a concentration of between 1 ng/ml and 1000 ng/ml.

### Claim 9 (depends on 1)

The method of claim 1, wherein said composition is formulated for delivery as a spray, irrigant, gel, or transdermal device.